Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Lab Accreditation Renewed

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Warnex said on Monday that its Medical Laboratories division's accreditation has been renewed by the US healthcare accreditation organization COLA.

COLA initially gave its accreditation, which exceeds or meets requirements under the clinical laboratory improvement amendments (CLIA) standards, to the Canadian company in 2007.

The accreditation covers standards for quality in day-to-day operations, requires accuracy in performance and proficiency, and includes an on-site lab survey. Its Medical Laboratories division provides specialized testing and lab services for the healthcare and pharmaceutical industries.

Warnex has facilities in Laval and Blainville in Quebec and at Thunder Bay in Ontario.

COLA is a non-profit, physician-directed organization that has been approved by the US government and is sponsored by the American Academy of Family Physicians, the American Medical Association, and other organizations, said Warnex.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.